• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    4/2/25 5:11:06 PM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email
    coo-20250402
    0000711404false00007114042025-04-022025-04-02

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
     
    _______________________________________________
    FORM 8-K
     _______________________________________________
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): April 2, 2025
    _______________________________________________
    THE COOPER COMPANIES, INC.
    (Exact name of registrant as specified in its charter)
     
    _______________________________________________
    Delaware1-859794-2657368
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    6101 Bollinger Canyon Road, Suite 500, San Ramon, California 94583
    (Address of principal executive offices, including Zip Code)
    (925) 460-3600
    (Registrant’s telephone number, including area code)
     
    _______________________________________________
    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading Symbol Name of each exchange on which registered
    Common Stock, $.10 par value COO Nasdaq Global Select Market


    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
                                            Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act. ☐



    ITEM 5.07. Submission of Matters to a Vote of Security Holders.


    On April 2, 2025, The Cooper Companies, Inc. (the "Company") held its Annual Meeting of Stockholders. The matters listed below were submitted to a vote of the stockholders through the solicitation of proxies, and the proposals are described in detail in the Company's definitive Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on February 19, 2025. Votes were cast by the stockholders as set forth below.


    Proposal 1 – Election of Directors

    The following individuals were elected to serve as directors of the Company until the 2026 Annual Meeting of Stockholders and until their successors have been duly elected and qualified.

    NomineeForAgainstAbstain
    Broker Non-Votes
    Colleen E. Jay173,530,482 6,663,082 131,725 4,883,871 
    Lawrence E. Kurzius174,883,981 5,356,269 85,039 4,883,871 
    Cynthia L. Lucchese169,387,137 10,795,377 142,775 4,883,871 
    Teresa S. Madden169,327,742 10,481,128 516,419 4,883,871 
    Maria Rivas, M.D.178,647,210 1,536,952 141,127 4,883,871 
    Robert S. Weiss170,745,141 9,065,734 514,414 4,883,871 
    Albert G. White III179,537,635 672,750 114,904 4,883,871 


    Proposal 2 – Approval of an Amendment to the Company's Second Restated Certificate of Incorporation to provide of the exculpation of officers


    ForAgainstAbstainBroker Non-Vote
    158,914,59821,339,31871,3734,883,871 

    Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm

    The appointment of KPMG LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2025 was ratified.

    ForAgainstAbstainBroker Non-Vote
    171,293,37913,420,877494,904-


    Proposal 4 – Advisory Vote on Executive Compensation

    The stockholders adopted, on an advisory basis, a resolution approving the compensation of the Company's Named Executive Officers as presented in the Proxy Statement.

    ForAgainstAbstainBroker Non-Vote
    162,444,65616,152,4041,728,2294,883,871 








    ITEM 9.01.    Financial Statements and Exhibits.

    (d)    Exhibits.

    ExhibitDescription
    104.1Cover Page Interactive Data File (embedded within the Inline XBRL document).






    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





        THE COOPER COMPANIES, INC.



        By:     /s/ Nicholas S. Khadder     
            Nicholas S. Khadder
    General Counsel & Secretary
            
    Dated: April 2, 2025






    Get the next $COO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    10/30/2023$380.00Buy
    BofA Securities
    10/5/2023$390.00 → $343.00Overweight → Neutral
    Redburn Atlantic
    5/30/2023$410.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/16/24 4:57:01 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by The Cooper Companies Inc.

      SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/24 10:04:33 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/13/24 5:02:29 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies to Participate in the William Blair Growth Stock Conference

      SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two bu

      5/8/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    SEC Filings

    See more
    • The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      4/30/25 4:21:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      4/2/25 5:11:06 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      3/7/25 4:22:17 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Financials

    Live finance-specific insights

    See more
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces First Quarter 2025 Results

      SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

      3/6/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for First Quarter 2025

      SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit

      2/3/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    See more
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

      SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

      11/30/23 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Carbone Barbara

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:16:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 3 filed by new insider Carbone Barbara

      3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:14:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:09:38 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Cooper with a new price target

      Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously

      8/29/24 8:24:13 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Jefferies with a new price target

      Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously

      7/16/24 7:26:08 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Cooper from Neutral to Buy and set a new price target of $125.00

      3/19/24 7:31:09 AM ET
      $COO
      Ophthalmic Goods
      Health Care